Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.

Molecular carcinogenesis - 1 Jan 2023

Chen Xi, Adhikary Gautam, Newland John J, Xu Wen, Ma Emily, Naselsky Warren, Eckert Richard L

Abstract excerpt

Transglutaminase 2 (TG2) is an important cancer stem-like cell survival protein that is highly expressed in epidermal squamous cell carcinoma and drives an aggressive cancer phenotype. In the present study, we show that TG2 knockdown or inactivation results in a reduction in mammalian target of rapamycin (mTOR) level and activity in epidermal cancer stem-like cells which are associated with reduced spheroid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Squamous Cell
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Epithelial-Mesenchymal Transition

Share to GTP-Binding Proteins

Share to Protein Glutamine gamma Glutamyltransferase 2

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 35848131
DOI: 10.1002/mc.23446
PMCID: PMC9771885

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.PMID 35848131Read ↗

Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype.Semantic proximity Read ↗

Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy targetSemantic proximity Read ↗

Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype.Semantic proximity Read ↗

Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and rewires the microenvironment toward an immune-suppressive stateSemantic proximity Read ↗

Tissue transglutaminase: a new target to reverse cancer drug resistanceSemantic proximity Read ↗

Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells.Semantic proximity Read ↗

REPS2 attenuates cancer stemness through inhibiting Wnt signaling by autophagy mediated degradation of β-cateninSemantic proximity Read ↗

Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem CellsSemantic proximity Read ↗

Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy.Semantic proximity Read ↗

ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancerSemantic proximity Read ↗

Signaling Node at TSC2 S1365 Potently Regulates T-Cell Differentiation and Improves Adoptive Cellular Cancer TherapySemantic proximity Read ↗

ASCL2 Maintains Stemness Phenotype through ATG9B and Sensitizes Gliomas to Autophagy Inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.